Rucaparib was first indicated for the treatment of advanced ovarian cancer with either germline or somatic BRCA1/2 mutations, and was then approved in 2018 for the maintenance treatment of platinum‐sensitive ovarian, fallopian tubal, and peritoneal cancer regardless of the BRCA status.137. The gene discussed is BRCA1; the disease is ovarian cancer.